Kioxia Holdings Corporation (TYO:285A)

Inozyme Pharma Cash Flow Statement

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Net Income	370,669	-	-	-	-
Depreciation & Amortization	312,307	-	-	-	-
Loss (Gain) From Sale of Assets	-6,853	-	-	-	-
Loss (Gain) on Equity Investments	-542	-	-	-	-
Other Operating Activities	-7,015	-	-	-	-
Change in Accounts Receivable	-89,361	-	-	-	-
Change in Inventory	-82,092	-	-	-	-
Change in Accounts Payable	-12,373	-	-	-	-
Change in Other Net Operating Assets	-8,324	-	-	-	-
Operating Cash Flow	476,416	-	-	-	-
Capital Expenditures	-223,847	-	-	-	-
Sale of Property, Plant & Equipment	8,820	-	-	-	-
Sale (Purchase) of Intangibles	-1,756	-	-	-	-
Other Investing Activities	43,772	-	-	-	-
Investing Cash Flow	-173,011	-	-	-	-
Long-Term Debt Issued	68,020	-	-	-	-
Short-Term Debt Repaid	-126,400	-	-	-	-
Long-Term Debt Repaid	-265,879	-	-	-	-
Total Debt Repaid	-392,279	-	-	-	-
Net Debt Issued (Repaid)	-324,259	-	-	-	-
Issuance of Common Stock	30,367	-	-	-	-
Other Financing Activities	-28,787	-	-	-	-
Financing Cash Flow	-322,679	-	-	-	-
Foreign Exchange Rate Adjustments	-387	-	-	-	-
Net Cash Flow	-19,661	-	-	-	-
Free Cash Flow	252,569	-	-	-	-
Free Cash Flow Margin	14.80%	-	-	-	-
Free Cash Flow Per Share	478.08	-	-	-	-
Cash Interest Paid	82,409	-	-	-	-
Cash Income Tax Paid	9,593	-	-	-	-
Levered Free Cash Flow	-159,502	-	-	-	-
Unlevered Free Cash Flow	-113,932	-	-	-	-
Change in Net Working Capital	478,540	-432,506	-97,201	-	-

Updated Feb 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.